Clinical Trials Directory

Trials / Completed

CompletedNCT01605864

Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

Ceftaroline Fosamil Versus Standard of Care for Community Acquired Bacterial Pneumonia (CABP): Clinical Outcomes Among Hospitalized Adults at a Single United States Hospital

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Albany Medical College · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Community-acquired bacterial pneumonia, which is often called CAP, is a bacterial infection in the lungs and is treated with antibiotics. Sometimes people need to be in the hospital to be treated for CAP. Usually, hospitalized persons with CAP are given two antibiotics together. These antibiotics usually include a cephalosporin and a macrolide. The most commonly used cephalosporin at Albany Medical Center Hospital is ceftriaxone. The most commonly used macrolides at Albany Medical Center Hospital are azithromycin and doxycycline. This research is being done to find out how well a new cephalosporin antibiotic, called ceftaroline, works in combination with a macrolide for the treatment of CAP. Ceftaroline is similar to ceftriaxone. Ceftaroline was recently approved by the FDA to treat pneumonia in hospitalized patients based on two research studies. In one study, ceftaroline was better than ceftriaxone. In the second study, ceftaroline was just as good as ceftriaxone. Ceftaroline was very well tolerated in both clinical studies and it was found to be as safe as ceftriaxone.

Conditions

Interventions

TypeNameDescription
DRUGEfficacy of ceftarolineDetermining the efficacy of ceftaroline compared to other cephalosporins

Timeline

Start date
2012-05-01
Primary completion
2013-03-01
Completion
2013-03-01
First posted
2012-05-25
Last updated
2014-03-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01605864. Inclusion in this directory is not an endorsement.